Study: Inflammatix' HostDx sepsis test can aid in diagnosis, risk of sepsis

Inflammatix announced Thursday study data, which suggest that risk assessment as well as diagnosis of sepsis can be improved with a gene expression model that measures the immune system's response to severe infection. CEO and lead author Tim Sweeney remarked that the study results, published in Nature Communications, "suggest that measuring immune dysregulation could indicate infection severity and significantly improve sepsis diagnosis." He added "the technology used in this study forms the basis of our HostDx sepsis test, which we plan to bring into hospitals and urgent care settings as a rapid test."

In the trial, gene-based models designed to accurately predict 30-day mortality were evaluated in patients with sepsis at the time of enrolment.  Inflammatix noted that the gene-based models were developed and assessed on over 20 cohorts from clinical trials involving extensive populations and settings. The company further said that it holds exclusive license to a pending patent from Stanford University for the gene expression model used in the study.  

The results showed that when combined with clinical severity scores, the gene expression model showed an increase in prognostic power for 30-day mortality, from 77 percent to 87 percent. "This would translate to an ability to rule out approximately 20 percent more sepsis cases, compared to clinical severity scores alone," Inflammatix said.

The company explained that the HostDx sepsis test, which detects the presence of a bacterial and/or viral infection and determines the severity of the infection, uses technology to measure the expression levels of numerous host immune genes in blood samples and then applies proprietary algorithms to produce results.  

Did you like this article?